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Abstract
Background: The degree of immune reconstitution achieved in response to suppressive ART is associated with
baseline individual characteristics, such as pre-treatment CD4 count, levels of viral replication, cellular activation,
choice of treatment regimen and gender. However, the combined effect of these variables on long-term CD4
recovery remains elusive, and no single variable predicts treatment response. We sought to determine if adiposity
and molecules associated with lipid metabolism may affect the response to ART and the degree of subsequent
immune reconstitution, and to assess their ability to predict CD4 recovery.
Methods: We studied a cohort of 69 (48 females and 21 males) HIV-infected, treatment-naïve South African
subjects initiating antiretroviral treatment (d4T, 3Tc and lopinavir/ritonavir). We collected information at baseline
and six months after viral suppression, assessing anthropometric parameters, dual energy X-ray absorptiometry and
magnetic resonance imaging scans, serum-based clinical laboratory tests and whole blood-based flow cytometry,
and determined their role in predicting the increase in CD4 count in response to ART.
Results: We present evidence that baseline CD4
+ T cell count, viral load, CD8
+ T cell activation (CD95 expression)
and metabolic and anthropometric parameters linked to adiposity (LDL/HDL cholesterol ratio and waist/hip ratio)
significantly contribute to variability in the extent of CD4 reconstitution (ΔCD4) after six months of continuous ART.
Conclusions: Our final model accounts for 44% of the variability in CD4
+ T cell recovery in virally suppressed
individuals, representing a workable predictive model of immune reconstitution.
Background
Chronic HIV infection is characterized by progressive
loss of CD4
+ T cells; suppression of viral replication
with antiretroviral agents results in most subjects in
rapid CD4 recovery [1] and decreased T cell activation
(e.g., CD38 expression [2]). Defective early recovery has
been demonstrated to be associated with increased mor-
bidity [3]; however, the extent of this recovery over time
is difficult to predict, as it likely depends on multiple
factors.
Baseline CD4+ T cell count remains the most relevant
predictor of clinical progression and survival in subjects
on antiretroviral therapy (ART) [4-8], but by itself it has
been shown to inadequately account for the variability
in ART-mediated immune restoration, and “on treat-
ment” assessment of CD4+ T cells retains a better prog-
nostic value [9]. Other factors positively associated with
CD4+ T cell immune reconstitution include the pre-
sence of specific genotypes, such as Δ32CCR5 [10], anti-
retroviral regimen [11] and, in some studies, pre-ART
viral load [12].
Immune activation of the T cell compartment (e.g.,
CD8
+ T cells), alterations of memory T cell subsets and
depletion of innate immune subsets (e.g., NK and
* Correspondence: montaner@mail.wistar.org
† Contributed equally
1HIV-1 Immunopathogenesis Laboratory, the Wistar Institute, Philadelphia,
PA, USA
Full list of author information is available at the end of the article
Azzoni et al. Journal of the International AIDS Society 2011, 14:37
http://www.jiasociety.org/content/14/1/37
© 2011 Azzoni et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.dendritic cells) are associated with advanced HIV infec-
tion [1,13-17]; however, while most of these cell subsets
are at least partially recovered on ART, even though
with different kinetics, their potential association with
early CD4 recovery has not been explored.
In addition to viral and immunologic parameters,
metabolic factors have been shown to be associated with
disease progression, and are putative candidates to pre-
dict CD4 recovery: advanced HIV infection (i.e., low
CD4 counts) is associated with chronic inflammation
and increased immune activation, with alteration of
metabolic parameters associated with lipid metabolism
and increased atherogenic risk (as assessed by increased
carotid intima-media thickness) in subjects of both
sexes [18,19]. A number of studies have reported that
subjects with advanced HIV infection have lower high-
density lipoprotein (HDL) cholesterol, higher low-
density lipoprotein (LDL) cholesterol and triglycerides
[20,21], and CD4 counts appear to directly correlate
with HDL cholesterol [22,23].
The existence of a relationship between metabolic
markers, viremia and immune activation is also sug-
gested by the observation that ART-mediated suppres-
sion of HIV replication results in a rapid normalization
of a number of markers linked to cardiovascular risk
[24].
While these observations highlight the negative effects of
HIV infection on lipid metabolism and overall atherogenic
risk, it is of note that cohort-based observations indicate
that high adiposity (which is normally associated with
insulin resistance, dyslipidemia and atherogenesis) might
be beneficial for HIV-infected individuals, contributing to
lower steady state viral replication and slower disease pro-
gression [25,26]. Altogether, these observations suggest
that adipose tissue accumulation and distribution may
affect the immunological host/virus equilibrium in chronic
HIV infection; however, the impact of adiposity on ART-
mediated immune reconstitution remains undefined.
In a reported multivariate analysis, subject age, nadir and
baseline CD4 count and initial viral load were found to be
inversely associated with early CD4 response to suppressive
ART [12]; importantly, the predictive value of subject gen-
der was ascribed to its effect on baseline CD4 measure-
ments [12,27]. Predictive logistic regression models for
incomplete CD4 response have been developed, based on
subject age, baseline CD4
+ T cell count and early CD4
response [28]; however, to our knowledge, there are at pre-
sent no satisfactory models that adequately predict early
(less than six months) CD4
+ T cell immune reconstitution.
To our knowledge, adiposity-associated metabolic markers
(e.g., BMI, serum lipid fractions, HOMA-2), have not used
in these models, and their predictive role remains unclear.
Based on the reported association of viremia and CD4
counts with body mass index (BMI) and serum lipid
levels, we sought to determine: (1) if adiposity and
markers associated with lipid metabolism can affect the
degree of early (six months [3]) immune reconstitution
after ART; and (2) if metabolic parameters could contri-
bute to a predictive model for immune reconstitution
that includes pre-ART viral, immune activation and
CD4
+ T cell counts. The present study followed a
cohort of ART-naïve, HIV-infected South African sub-
jects. We demonstrate that metabolic parameters mea-
sured before ART have a significant effect on the degree
of immune reconstitution attained after six months of
continuous ART and contribute significantly to a pre-
dictive model of CD4
+ T cell immune reconstitution.
Methods
Study subjects
We assessed 69 ART-naïve, HIV-infected subjects initiat-
ing ART (d4T, 3TC and lopinavir/ritonavir) at the Clini-
cal HIV Research Unit of the Themba Lethu Clinic,
Johannesburg, South Africa (21 males, 48 females). Medi-
cal history was obtained from the clinic record and by
interview. Written informed consent was obtained from
all participants as per University of the Witwatersrand
Ethics Committee- and Wistar Institute Institutional
Review Board-approved study protocol.
Adiposity measurements
Baseline height, weight and anthropometric measurements
were obtained pre-ART by trained study personnel; BMI
was calculated as weight (kg) divided by height (m)
2. Dual
energy X-ray absorptiometry (DEXA) scans were per-
formed using a Hologic QDR-2000 scanner, assessing limb
and trunk fat and lean mass. Magnetic resonance imaging
(MRI) scans were performed using a Toshiba Flexart
0.5 T; a single L4-L5 axial section was used to determine
sagittal diameter, visceral, subcutaneous, total abdominal
and peri-renal fat. The analysis was conducted using
V3.51*R553 software.
Clinical laboratory testing
CD4 counts were assessed at baseline (CD4BL, last
available measurement prior to ART initiation) and
approximately 36 weeks from ART initiation (range
220-259 days; CD4END), using the single platform
method described by Scott and Glencross [29]. Serum
from fasting blood draws was tested for HDL choles-
terol, triglycerides and glucose using a Roche Integra
analyzer 400 (Roche Diagnostics, Mannheim, Germany);
LDL cholesterol was estimated using the Friedewald for-
mula [30]. HIV-1 infection was confirmed via rapid anti-
body testing and/or ultra-sensitive PCR, (Roche COBAS
Ampliprep/COBAS Amplicor v1.5 methods), with viral
load suppression to < 50 copies/ml on ART confirmed
every eight weeks.
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Four-colour flow cytometry stainings to assess immunolo-
gical parameters were performed on whole blood using
custom-made lyoplates (BD Biosciences, Palo Alto, CA).
The following antibody combinations were used for the
specified target populations: T cell activation/differentia-
tion: CD8, CD28, CD3, CD38; and T cell activation: CD8,
CD95, CD3, HLA-DR. After RBC lysis, sample fluores-
cence data were acquired with a FACScalibur flow cyt-
ometer and analyzed using CellQuest software (BD
Biosciences). Isotype-matched control antibodies were
used as negative controls for gate positioning.
Statistical analysis
Summary statistics (mean, standard deviation, median,
min and max) are reported for each independent vari-
able (listed in Table 1) at baseline. Simple linear regres-
sion models were fitted to the primary endpoint ΔCD4
(ΔCD4 = endpoint CD4 count - baseline CD4 count).
Multivariable models were generated using an iterative,
stepwise model building procedure, combining forward
and backward selection [31]. Differences in time to sup-
pression by BMI category were assessed using a Kaplan
Meier test. All statistical tests were performed using R
vers. 2.10.0 [32].
Results
Cohort characteristics
The baseline characteristics of our cohort are summar-
ized in Table 1. The median baseline CD4 count
(CD4BL) was 243 cells/mm
3,w i t ham e d i a nl o g 10VL
(log10VLBL) of 4.7. Median BMI was 26.8kg/m
2,w i t h
70% of the cohort being overweight or obese (48 of 69
subjects with BMI > 25); median LDL/HDL ratio was
1.8, and median serum fasting glucose was 4.2 mmol/l.
According to the Adult Treatment Panel III guidelines
[33], 65% of the subjects (45 of 69) had low HDL cho-
lesterol levels [61% < 1mM (male) or < 1.3 mM
(female)], 3% of the subjects had elevated triglycerides
(≥ 1.7 mM), 3% had elevated total cholesterol (≥ 5.0
mM), and 7% had elevated LDL cholesterol (≥ 3.0 mM).
After 24 weeks of ART, the median endpoint CD4
count (CD4END) was 421 cells/mm
3 (interquartile range:
355-505), with a median gain (ΔCD4) of 172 (IQR 92-
247) CD4
+ T cells; five subjects (5.2%) failed to gain
CD4 on ART in the presence of viral suppression
(immunological failure). As expected, the spread of the
distribution in CD4 gain after ART supports the hypoth-
esis that, in addition to viral suppression alone, other
factors may determine the extent of immune reconstitu-
tion on ART.
Baseline CD4 count, viral load and cellular activation
affect immune reconstitution in response to ART
The unadjusted effects of baseline characteristics on
ART-mediated immune reconstitution, as measured by
ΔCD4 count, are summarized in Table 2. As expected,
the effect of log10VLBL on ΔCD4 was observed to be posi-
tive (effect estimate 56.0, corresponding to an increase of
56 CD4
+ Tc e l l s / m m
3 in ΔC D 4p e rl o go fV L ;p=0 . 0 0 2 ;
adjusted R
2 = 0.12), suggesting that subjects with high
levels of viral replication had the most benefit from phar-
macological suppression in terms of CD4 recovery. Con-
versely, lower baseline CD4BL correlated with higher
Table 1 Baseline (pre-ART) cohort characteristics
Variable 25th quantile Median 75th quantile Mean Standard deviation
Gender (female/male ratio) 2.29 (48/21)
Age (years) 29.0 33.0 39.0 34.6 8.2
Baseline CD4 count (cells/mm
3) 221.0 243.0 292.0 259.8 61.6
Baseline log10 VL 4.0 4.7 5.1 4.5 0.8
Total fat mass (DEXA, g) 9356.1 19451.7 28589.5 20719.7 11801.5
Total lean mass (DEXA, g) 39458.8 42455.1 48867.2 43582.5 6038.0
Fat ratio (DEXA, %) 16.2 32.7 39.5 29.6 12.6
Total abdominal fat (MRI, cm
2) 144.0 294.7 414.6 311.3 191.3
Cholesterol (mmol/L) 3.1 3.5 4 3.6 0.8
HDL-associated cholesterol (mmol/L) 0.9 1.1 1.3 1.1 0.3
LDL-associated cholesterol (mmol/L) 1.6 2.1 2.5 2.1 0.7
Triglycerides (mmol/L) 0.6 0.8 1 0.8 0.3
LDL/HDL cholesterol ratio 1.5 1.8 2.6 2.3 2.7
Waist circumference (cm) 73.0 78.5 87.5 80.9 11.3
Waist/hip ratio 0.7 0.8 0.8 0.8 0.1
Fasting glucose (mmol/l) 4.0 4.2 4.4 4.3 0.6
BMI (kg/m
2) 24.5 26.8 29.9 28.1 5.1
CD95
+ CD8
+ T cells (%) 81.9 89.9 95.9 85.7 14.6
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of 0.61 CD4
+ T cells/mm
3 in ΔCD4 per unit of CD4BL;
p = 0.008; R
2 0.08), indicating a greater benefit of therapy
in these subjects.
Baseline levels of CD95
+ CD8
+ T cells, an immune
activation parameter previously shown to predict pDC
recovery on ART [34], had a significant positive effect
on ΔCD4 (Table 2; effect estimate 3.14, p = 0.001), and
had a predictive association with CD4 (adj. R
2 = 0.13).
We did not detect a significant association of CD38 or
HLA-DR expression on CD4
+ or CD8
+ T cells with
CD4 outcomes (not shown).
Effect of metabolic and anthropometric parameters on
immune reconstitution outcomes
As summarized in Table 2 a meaningful negative asso-
ciation with ΔCD4 was observed for waist/hip ratio
(effect estimate -458.1, p = 0.015, adjusted R
2 = 0.072);
no association was observed for BMI or gender, suggest-
ing that the relationship is limited to central adiposity,
as assessed by waist/hip ratio. LDL/HDL cholesterol
ratio (effect estimate -9.432, p = 0.083, adjusted R
2 =
0.03) was also associated with ΔCD4, unlike other lipid
measures (not shown).
To assess if the observed negative effect of central adip-
osity (i.e., waist/hip ratio) and lipid indicators could be
associated with incomplete or delayed suppression of viral
load below 50 copies/ml, we compared the proportion of
individuals achieving viral suppression (VL < 400 c/ml)
over time between normal/underweight, overweight and
obese subjects, using a Kaplan-Meier analysis. The survival
curves were not significantly different (Figure 1). In addi-
tion, we could not detect an association between BMI or
waist/hip ratio and time to suppression (not shown).
Thus, our data do not support the conclusion that the
negative effect of central adiposity on CD4 immune recon-
stitution observed in this cohort is caused by differences in
rates of virological suppression.
Multivariable analysis of predictors of CD4 recovery on
ART
We used a multivariable approach to estimate the com-
bined effect of multiple baseline variables on CD4 recov-
ery on ART. The adjusted R
2 of each model tested is
reported in Table 3; together, CD4BL and log10VLBL
accounted for approximately 18% of the variability in
ΔCD4 (adj. R
2 = 0.1828). We also observed a significant
interaction between CD4BL and log10VLBL (Figure 2),
indicating that the effect of an increase in log10VLBLon
ΔCD4 was greater among individuals with lower CD4BL
than among individuals with higher CD4BL; modelling
this interaction improved the model predictivity to
approximately 22% (adj. R
2 = 0.219). As CD8
+ Tc e l l
activation has been associated with clinical outcomes in
past studies, we tested whether including in this model
the frequency of CD95
+ CD8
+ T cells, the only activa-
tion term individually associated with the ΔCD4 out-
come, would improve the predictivity of CD4BL and
VLBL: our results indicate an adj. R
2 of 0.2751 for the
combined model, supporting the use of an activation
term.
The metabolic terms, LDL/HDL cholesterol ratio and
waist/hip ratio, together accounted for 11% of ΔCD4
variability (adj. R
2 = 0.1122, similar to CD4BL alone);
when both metabolic parameters were added to CD4BL
and VLBL, the model accounted for almost 37% of
ΔCD4 variability (adj. R
2 = 0.3673), confirming the role
of these metabolic terms as outcome predictors.
The final model, selected for best fit by assessing the
models’ -2 log likelihood (see Table 4) included CD4BL,
log10VLBL, LDL/HDL ratio, waist/hip ratio and CD95
+
CD8
+ T cells, in addition to an interaction term between
CD4BL and log10VLBL: all of the variables selected had a
significant independent effect on the ΔCD4; the interac-
tion CD4BL and log10VLBL also remained significant.
This model accounted for almost 44% of the variability
in ΔCD4 (R
2 = 0.4377), which is approximately twice as
much as the best performing CD4BL and log10VLBL-
based model, and 1.6 times greater than the model
including CD4BL,l o g 10VLBL and CD95 expression. The
addition of an interaction term between CD4BL and
CD95
+ CD8
+ T cells resulted in a further increase of the
model predictivity (adj. R
2 = 0.46, not shown), but as the
effect of the interaction term per se was not significant
(p = 0.057), it was not included in the final model.
Discussion
We report that a multivariable model using pre-ART
viral load, immunological parameters and metabolic
Table 2 Association of baseline variables with ΔCD4:
model fitting with single variables
Predictor Estimate S.E. Pr(> |t|) Adjusted R
2
Age -2.773 1.751 0.1180 0.0217
Sex -26.283 31.231 0.4030 -0.0043
CD4BL -0.607 0.224 0.0085 0.0854
Log10VL 56.048 17.110 0.0017 0.1252
Total fat mass (DEXA) 0.000 0.001 0.8935 -0.0147
Total lean mass (DEXA) -0.002 0.002 0.3068 0.0009
Total fat % (DEXA) 0.745 1.148 0.5184 -0.0086
Total abdominal fat (MRI) -0.007 0.076 0.9293 -0.0148
LDL/HDL ratio -9.432 5.358 0.0829 0.0299
Waist circumference -1.128 1.281 0.3817 -0.0033
Waist/hip ratio -458.084 183.071 0.0148 0.0718
Fasting glucose -28.171 23.307 0.2310 0.0067
BMI -0.962 2.828 0.7348 -0.0132
CD95
+ CD8
+ T cells 3.136 0.919 0.0011 0.1354
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initiating ART to a substantially higher degree than pre-
viously reported models. The variability of the extent of
immune reconstitution levels (i.e., CD4 gain) in response
to ART-mediated viral suppression, confirmed in our
cohort, suggests that a number of factors, in addition
to successful viral suppression, might affect the extent of
immune recovery. Pre-treatment CD4 counts, viral
load and immune activation are recognized to play a
role in determining the levels of immune recovery
[8,10,12,34-36], but individually they have limited useful-
ness as predictors of early CD4 recovery [9]. All indivi-
duals in our cohort received the same ART regimen, thus
ruling out effects of post-ART CD4 recovery linked to
differences in treatment regimens, as observed in other
studies [11].
Our results confirm that pre-ART VL, CD4 count and
cellular activation (i.e., CD95 expression [37,38]), alone
or in combination, have a significant, but limited value in
predicting the CD4
+ T cell recovery outcome, explaining
only 21% of its variability. The effect of baseline CD4 on
ΔCD4 was negative, confirming a prior report [39];
unlike earlier studies [8], we did not assess the effect of
baseline CD4
+ T cell levels on CD4 immune reconstitu-
tion, which was found to be positive, as we considered
ΔCD4 (a measure incorporating CD4BL) more relevant to
assessing an immune reconstitution response. Prior stu-
dies have reported an effect of age and gender on CD4
outcomes of treatment [12,27]; while we failed to detect
such associations in our cohort, the difference in out-
come measured (ΔCD4 vs. CD4 count at endpoint) is
likely responsible for this discrepancy.
We found a meaningful negative association between
LDL/HDL ratio and CD4
+ T cell recovery. While this
finding is novel, associations of lipid levels and viral
replication have been reported [40-43], suggesting the
possibility that the observed relationship between LDL/
HDL ratios and immune recovery may result in part
from direct effects on viral function. A number of stu-
dies have demonstrated the effects of membrane choles-
terol and lipid rafts on viral penetration and/or budding
[44-46]. Moreover, apolipoprotein A1, a component of
HDL, has been shown to directly affect the viral life
cycle at the viral entry and syncytium formation stages
[47-49]). A recent study indicated an association of
hypocholesterolemia with a reduced response to ART
[50], and studies with cholesterol-lowering agents have
shown mixed results [51-56].
Adiposity has generally been associated with better
viral control and slower disease progression in ART-
naïve, HIV-positive subjects [25,26,57,58]. While in our
cohort, BMI did not predict ΔCD4 in response to ART,
in keeping with a prior report that did not detect a lack
of response to ART in obese subjects [59], we did
observe a negative association between waist/hip ratio
and CD4 gain, indicating that subjects with low waist to
hip ratios (i.e., with low central adiposity) are likely to
have better immunologic recovery. One possible
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Figure 1 Effect of BMI on the time to ART-mediated
suppression. The proportion (%) of viremic subjects was assessed
at each study visit for six months following ART initiation. Kaplan-
Meier curves are displayed for normal/underweight (BMI < 25 kg/
m
2; n = 21; continuous line), overweight (BMI 25-30 kg/m
2; n = 31;
dashed line) and obese (BMI > 30 kg/m
2; n = 17; dotted line).
Differences between curves are not significant.
Table 3 Adjusted R
2 for linear models of ΔCD4
Variable(s) included as predictors Adjusted R
2 -2 log ^L
CD4BL 0.0854 847.28
log10VL 0.1252 844.20
CD4BL + log10VL 0.1828 838.47
CD4BL + log10VL + (CD4BL × Log10VL)
a 0.2190 834.29
CD4BL + log10VL + (CD4BL × Log10VL) + Waist/hip ratio 0.2453 830.85
CD4BL + log10VL + (CD4BL × Log10VL) + LDL/HDL ratio 0.3380 828.08
CD4BL + log10VL + (CD4BL × Log10VL) + CD8
+CD95
+ T cells 0.2751 821.81
CD4BL + log10VL + (CD4BL × Log10VL) + LDL/HDL ratio + Waist/hip ratio 0.3673 817.60
CD4BL + log10VL + (CD4BL × Log10VL) + LDL/HDL ratio + Waist/hip ratio + CD8
+CD95
+ T cells 0.4377 808.36
a: interaction term
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waist/hip ratio predictive values is that antiretroviral
drugs may be metabolized differently or be less bio-
available in subjects with higher central adiposity (i.e.,
high waist/hip ratio). It is also possible that abdominal
adipose tissue, particularly the visceral depot, secretes
factors that may modulate the effects of the ART or
directly interfere with immune reconstitution [60].
While we did not evidence significant differences in
time to viral suppression to < 50 c/ml between normal,
overweight and obese subjects (Figure 1), we cannot
exclude that metabolic events may be associated with
residual levels of viral replication, affecting in turn
short-term CD4 recovery. Importantly, the overall HDL-
cholesterol values in our cohort were low, with 61% of
the subjects being classified as dyslipidemic [33], in
keeping with prior reports in HIV-infected African
populations [61,62], and there was a high prevalence of
overweight/obesity [63] (79% of women and 48% of men
had BMI > 25 kg/m
2). Based on these observations, as
well as the present contribution, further studies in larger
cohorts will be necessary to determine if metabolic para-
meters play the same role in low-central adiposity indi-
viduals, and to further explore the relationship between
lipids and viral control.
Altogether our data indicate that metabolic parameters
contribute to predicting the degree of immune reconsti-
tution achieved upon viral suppression. While our study
does not address the pathophysiologic mechanisms
underlying this relationship, prior reports indicate that
fat accumulation promotes low-level inflammation,
which, in turn, has been shown to be associated with
lack of immunologic reconstitution [38], suggesting a
possible biological pathway.
By including pre-ART metabolic parameters in conjunc-
tion with baseline CD4, viral load and immune activation,
our final model accounts for 44% of the variability in CD4
+ T cell gain in response to viral suppression, representing,
to our knowledge, the best predictive model on immune
reconstitution to date, and represents a marked improve-
ment over more conventional assessments (e.g., baseline
CD4
+ T cell counts alone or with viral load).
While not designed to support clinical interventions,
our results, if supported by validation in a larger cohort,
suggest the testable hypothesis that clinical and beha-
vioural interventions aimed at reducing weight in sub-
jects with central adiposity, as well as pharmacological
intervention aimed at improving LDL/HDL ratios (e.g.,
statins), might improve the immunological outcomes or
ART, at least in the short term.
As with all modeling techniques, there are limitations
to our findings. In the first place, we modeled the effect
of the assessed variables on the change in CD4 between
baseline and six months on ART: it remains to be deter-
mined if incorporating multiple early CD4 measurements
would improve the predictivity of the model. Moreover,
the predictive value of the model will have to be validated
in a larger independent cohort.
In addition, due to the relatively small size of the
study, we did not assess the effect of clinical conditions
that could affect some of the parameters studies here
(e.g., hypertension, diabetes).
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Figure 2 Mixed effect modelling of the effect of baseline CD4
percentile and viral load on CD4+ T cell reconstitution. The
complete model (Table 3) was fitted to the data: linear predicted
ΔCD4 as a function of log10VL is plotted for baseline CD4 count =
25
th quantile (circles), 50 quantile (squares) and 75 quantile
(triangles) of the baseline CD4 distribution.
Table 4 Multivariable analysis: complete model
parameter estimates
Coefficient Estimate Standard error p
Intercept -721.3331 372.7459 0.0575
CD4BL 2.8829 1.2345 0.0228
log10VLBL 238.3317 72.7549 0.0017
CD4BL × log10VLBL -0.7369 0.2753 0.0095
LDL/HDL ratio -17.3449 4.2669 0.0001
Waist/hip ratio -294.0370 146.6771 0.0494
CD95
+ CD8
+ T cells 2.3330 0.7827 0.0041
Adjusted R
2 = 0.4377
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mechanistically and whether additional predictors may
improve the reliability of the prediction.
Conclusions
We report for the first time that metabolic markers can
contribute significantly to the variability of immune
reconstitution outcomes following ART initiation in a
cohort of HIV-1-infected South African subjects. While
the current study clearly establishes the predictive
potential for metabolic markers, further studies will be
required to determine the cost effectiveness of this pre-
dictive approach, and to determine whether additional
longitudinal measurement would further improve the
model performance.
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